Charles University in Prague-ko ikertzaileekin lankidetzan egindako argitalpenak (69)

2024

  1. ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study

    Haematologica, Vol. 109, Núm. 3, pp. 867-876

  2. Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study

    Haematologica, Vol. 109, Núm. 3, pp. 895-905

  3. Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: A prospective study

    Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 1

  4. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet, Vol. 403, Núm. 10423, pp. 249-260

  5. Non-apoptotic FAS signaling controls mTOR activation and extrafollicular maturation in human B cells

    Science Immunology, Vol. 9, Núm. 91

2023

  1. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031

  2. Identification of novel genetic loci for risk of multiple myeloma by functional annotation

    Leukemia

  3. MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials

    Blood, Vol. 141, Núm. 6, pp. 579-591

  4. Overall Survival with Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial

    Journal of Clinical Oncology, Vol. 41, Núm. 8, pp. 1600-1609

  5. Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization

    International Journal of Molecular Sciences, Vol. 24, Núm. 10

  6. Stratification of adolescents across mental phenomena emphasizes the importance of transdiagnostic distress: a replication in two general population cohorts

    European Child and Adolescent Psychiatry, Vol. 32, Núm. 5, pp. 797-807

  7. Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma

    Journal of Oncology Pharmacy Practice, Vol. 29, Núm. 5, pp. 1172-1177

2022

  1. Determinants of patient-reported outcome trajectories and symptomatic recovery in Improving Access to Psychological Therapies (IAPT) services

    Psychological Medicine, Vol. 52, Núm. 14, pp. 3231-3240

  2. Developing a Web-Based App to Assess Mental Health Difficulties in Secondary School Pupils: Qualitative User-Centered Design Study

    JMIR Formative Research, Vol. 6, Núm. 1

  3. Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma

    Haematologica, Vol. 107, Núm. 10, pp. 2408-2417

  4. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

    The Lancet Haematology, Vol. 9, Núm. 2, pp. e98-e110

  5. On Dimensionality, Measurement Invariance, and Suitability of Sum Scores for the PHQ-9 and the GAD-7

    Assessment, Vol. 29, Núm. 3, pp. 355-366

  6. The impact of the initial COVID-19 outbreak on young adults’ mental health: a longitudinal study of risk and resilience factors

    Scientific Reports, Vol. 12, Núm. 1

  7. Treating common mental disorder including psychotic experiences in the primary care improving access to psychological therapies programme (the TYPPEX study): protocol for a stepped wedge cluster randomised controlled trial with nested economic and process evaluation of a training package for therapists

    BMJ open, Vol. 12, Núm. 6, pp. e056355

2021

  1. Development and external validation of the Psychosis Metabolic Risk Calculator (PsyMetRiC): a cardiometabolic risk prediction algorithm for young people with psychosis

    The Lancet Psychiatry, Vol. 8, Núm. 7, pp. 589-598